Human TPP1 adenoviral particles

The TPP1 gene encodes tripeptidyl peptidase 1, a lysosomal enzyme essential for protein degradation. TPP1 is a serine protease that cleaves tripeptides from the N-terminus of substrates and plays an important role in maintaining cellular homeostasis. Mutations in the TPP1 gene are associated with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a severe neurodegenerative disease characterized by lysosomal storage disorders, seizures, and progressive cognitive decline. The importance of this gene in lysosomal function makes it a target for gene therapy research, especially in the treatment of CLN2 and related lysosomal storage disorders. Understanding the molecular mechanisms of TPP1 is essential for the development of therapeutic interventions, including adenoviral vector-based therapies.

Human TPP1 adenoviral particles are genetically engineered viral vectors designed to deliver the TPP1 gene to target cells. Derived from a non-replicating adenovirus, these particles take advantage of the high transduction efficiency and broad tropism of the virus to ensure stable gene expression in both dividing and non-dividing cells. These particles contain a recombinant adenoviral genome in which the TPP1 cDNA is under the control of a strong promoter, enabling sustained production of the TPP1 enzyme. Such vectors are essential in preclinical studies of CLN2 disease and offer potential therapeutic benefit by restoring lysosomal enzyme activity.